Comprehensive review of targeted therapy for colorectal cancer
YH Xie, YX Chen, JY Fang - Signal transduction and targeted therapy, 2020 - nature.com
Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …
Lung cancer: current therapies and new targeted treatments
Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1· 8
million people are diagnosed with lung cancer, and 1· 6 million people die as a result of the …
million people are diagnosed with lung cancer, and 1· 6 million people die as a result of the …
[HTML][HTML] Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms
Cancer-associated fibroblasts (CAFs) are highly heterogeneous. With the lack of a
comprehensive understanding of CAFs' functional distinctions, it remains unclear how …
comprehensive understanding of CAFs' functional distinctions, it remains unclear how …
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for …
We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an
acquired CCDC6–RET fusion. Although RET fusions have been identified in resistant EGFR …
acquired CCDC6–RET fusion. Although RET fusions have been identified in resistant EGFR …
The advantages of targeted protein degradation over inhibition: an RTK case study
Proteolysis targeting chimera (PROTAC) technology has emerged over the last two decades
as a powerful tool for targeted degradation of endogenous proteins. Herein we describe the …
as a powerful tool for targeted degradation of endogenous proteins. Herein we describe the …
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Abstract c-Met is a receptor tyrosine kinase belonging to the MET (MNNG HOS transforming
gene) family, and is expressed on the surfaces of various cells. Hepatocyte growth factor …
gene) family, and is expressed on the surfaces of various cells. Hepatocyte growth factor …
MET-dependent solid tumours—molecular diagnosis and targeted therapy
Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
PM Comoglio, L Trusolino, C Boccaccio - Nature Reviews Cancer, 2018 - nature.com
The MET oncogene encodes an unconventional receptor tyrosine kinase with pleiotropic
functions: it initiates and sustains neoplastic transformation when genetically altered …
functions: it initiates and sustains neoplastic transformation when genetically altered …
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
D Planchard, TM Kim, J Mazieres, E Quoix… - The Lancet …, 2016 - thelancet.com
Summary Background Activating BRAF V600E (Val600Glu) mutations are found in about 1–
2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in …
2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in …
[HTML][HTML] Targeting MET in lung cancer: will expectations finally be MET?
The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of
cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a …
cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a …